Neuro-oncology practice最新文献

{"title":"Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma.","authors":"Joy C Zhang, Matthew J Stotts, Bethany Horton, David Schiff","doi":"10.1093/nop/npad008","DOIUrl":"10.1093/nop/npad008","url":null,"abstract":"<p><strong>Background: </strong>High-dose methotrexate (HDMTX) is a mainstay of primary central nervous system lymphoma (PCNSL) treatment. Transient hepatotoxicity from HDMTX has been characterized in pediatric patients but not in adults. We sought to characterize hepatotoxicity in adult PCNSL patients undergoing HDMTX treatment.</p><p><strong>Methods: </strong>Retrospective study of 65 PCNSL patients treated at the University of Virginia from 02/01/2002 to 04/01/2020 was performed. Hepatotoxicity was defined using National Cancer Institute Common Toxicity Criteria (CTC) for adverse events, fifth version. High-grade hepatotoxicity was defined as a bilirubin or aminotransferase CTC grade of 3 or 4. Relationships between clinical factors and hepatotoxicity were assessed with logistic regression.</p><p><strong>Results: </strong>Most patients (90.8%) had a rise of at least one aminotransferase CTC grade during HDMTX treatment. 46.2% had high-grade hepatotoxicity based on aminotransferase CTC grade. No patients developed high-grade bilirubin CTC grades during chemotherapy. Liver enzyme test values decreased to low CTC grade or normal in 93.8% of patients after the conclusion of HDMTX treatment without treatment regimen changes. Prior ALT elevation (<i>P</i> = .0120) was a statistically significant predictor of high-grade hepatotoxicity during treatment. Prior history of hypertension was associated with increased risk of toxic serum methotrexate levels during any cycle (<i>P</i> = .0036).</p><p><strong>Conclusions: </strong>Hepatotoxicity develops in the majority of HDMTX-treated PCNSL patients. Transaminase values decreased to low or normal CTC grades in almost all patients after treatment, without modification of MTX dosage. Prior ALT elevation may predict patients' increased hepatotoxicity risk, and hypertension history may be a risk factor for delayed MTX excretion.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"291-300"},"PeriodicalIF":2.4,"publicationDate":"2023-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9829719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of an enhanced recovery protocol after laser ablation surgery protocol: a preliminary analysis.","authors":"Adam S Levy, Martin A Merenzon, Tiffany Eatz, Alexis A Morell, Daniel G Eichberg, Marc J Bloom, Ashish H Shah, Ricardo J Komotar, Michael E Ivan","doi":"10.1093/nop/npad007","DOIUrl":"10.1093/nop/npad007","url":null,"abstract":"<p><strong>Background: </strong>Enhanced recovery after surgery (ERAS) programs are a model of care that aim to improve patient outcomes, reduce complications, and facilitate recovery while reducing healthcare-associated costs and admission length. While such programs have been developed in other surgical subspecialties, there have yet to be guidelines published specifically for laser interstitial thermal therapy (LITT). Here we describe the first multidisciplinary ERAS preliminary protocol for LITT for the treatment of brain tumors.</p><p><strong>Methods: </strong>Between the years 2013 and 2021, 184 adult patients consecutively treated with LITT at our single institution were retrospectively analyzed. During this time, a series of pre, intra, and postoperative adjustments were made to the admission course and surgical/anesthesia workflow with the goal of improving recovery and admission length.</p><p><strong>Results: </strong>The mean age at surgery was 60.7 years with a median preoperative Karnofsky performance score of 90 ± 13. Lesions were most commonly metastases (50%) and high-grade gliomas (37%). The mean length of stay was 2.4 days, with the average patient being discharged 1.2 days after surgery. There was an overall readmission rate of 8.7% with a LITT-specific readmission rate of 2.2%. Three of 184 patients required repeat intervention in the perioperative period, and there was one perioperative mortality.</p><p><strong>Conclusions: </strong>This preliminary study shows the proposed LITT ERAS protocol to be a safe means of discharging patients on postoperative day 1 while preserving outcomes. Although future prospective work is needed to validate this protocol, results show the ERAS approach to be promising for LITT.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 3","pages":"281-290"},"PeriodicalIF":2.7,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9549555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MGMT methylation: Is it time to embrace the shades of grey?","authors":"Hui K Gan","doi":"10.1093/nop/npad003","DOIUrl":"10.1093/nop/npad003","url":null,"abstract":"","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 2","pages":"111-112"},"PeriodicalIF":2.7,"publicationDate":"2023-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9561116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and survival of choroid plexus tumors in the United States.","authors":"Kailey Takaoka,&nbsp;Gino Cioffi,&nbsp;Kristin A Waite,&nbsp;Jonathan L Finlay,&nbsp;Daniel Landi,&nbsp;Kaitlyn Greppin,&nbsp;Carol Kruchko,&nbsp;Quinn T Ostrom,&nbsp;Jill S Barnholtz-Sloan","doi":"10.1093/nop/npac062","DOIUrl":"https://doi.org/10.1093/nop/npac062","url":null,"abstract":"<p><strong>Background: </strong>There are limited data available on incidence and survival of patients with choroid plexus tumors (CPT). This study provides the most current epidemiological analysis of choroid plexus tumors from 2004 to 2017 in the United States.</p><p><strong>Methods: </strong>Data on 2013 patients with CPT were acquired from the Central Brain Tumor Registry of the United States in collaboration with the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute, from 2004 to 2017. CPT cases were classified by the following pathological subtypes: choroid plexus papilloma (CPP), atypical choroid plexus papilloma (aCPP), and choroid plexus carcinoma (CPC). Frequencies and age-adjusted incidence rates (AAIR) per 100 000 and rate ratios per 100 000 (IRR) were reported for age, sex, race, and ethnicity for each pathological subtype with 95% confidence intervals (95% CI). Using CDC's National Program of Cancer Registries survival database, survival curves and hazard ratios (HRs) evaluated overall survival from 2001 to 2016.</p><p><strong>Results: </strong>CPP had the highest overall incidence (AAIR: 0.034, 95% CI: 0.033-0.036), followed by CPC (AAIR: 0.008, 95% CI: 0.008-0.009) and aCPP (AAIR: 0.005, 95% CI: 0.005-0.006). Incidence was highest among children less than one year old among all subtypes (CPP AAIR: 0.278; aCPP AAIR: 0.140; CPC AAIR: 0.195), reducing as patients aged. Overall survival was worse among patients with CPC, being five times more likely to die compared to patients with CPP (HR: 5.23, 95% CI: 4.05-7.54, <i>P</i> < .001).</p><p><strong>Conclusions: </strong>This analysis is the most current and comprehensive study in the US on the incidence and survival for CPT. Population based statistics provide critical information in understanding disease characteristics, which impact patient care and prognosis.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"41-49"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837781/pdf/npac062.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9929965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of care and survival of Chinese glioblastoma patients in the temozolomide era: a Hong Kong population-level analysis over a 14-year period.","authors":"Peter Y M Woo,&nbsp;Stephen Yau,&nbsp;Tai-Chung Lam,&nbsp;Jenny K S Pu,&nbsp;Lai-Fung Li,&nbsp;Louisa C Y Lui,&nbsp;Danny T M Chan,&nbsp;Herbert H F Loong,&nbsp;Michael W Y Lee,&nbsp;Rebecca Yeung,&nbsp;Carol C H Kwok,&nbsp;Siu-Kie Au,&nbsp;Tze-Ching Tan,&nbsp;Amanda N C Kan,&nbsp;Tony K T Chan,&nbsp;Calvin H K Mak,&nbsp;Henry K F Mak,&nbsp;Jason M K Ho,&nbsp;Ka-Man Cheung,&nbsp;Teresa P K Tse,&nbsp;Sarah S N Lau,&nbsp;Joyce S W Chow,&nbsp;Aya El-Helali,&nbsp;Ho-Keung Ng,&nbsp;Wai-Sang Poon","doi":"10.1093/nop/npac069","DOIUrl":"https://doi.org/10.1093/nop/npac069","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to address the paucity of epidemiological data regarding the characteristics, treatment patterns and survival outcomes of Chinese glioblastoma patients.</p><p><strong>Methods: </strong>This was a population-level study of Hong Kong adult (<i>></i>18 years) Chinese patients with newly diagnosed histologically confirmed glioblastoma between 2006 and 2019. The age standardized incidence rate (ASIR), patient-, tumor- treatment-related characteristics, overall survival (OS) as well as its predictors were determined.</p><p><strong>Results: </strong>One thousand and ten patients with a median follow-up of 10.0 months were reviewed. The ASIR of glioblastoma was 1.0 per 100 000 population with no significant change during the study period. The mean age was 57 <i>+</i> 14 years. The median OS was 10.6 months (IQR: 5.2-18.4). Independent predictors for survival were: Karnofsky performance score <i>></i>80 (adjusted OR: 0.8; 95% CI: 0.6-0.9), <i>IDH-1</i> mutant (aOR: 0.7; 95% CI: 0.5-0.9) or <i>MGMT</i> methylated (aOR: 0.7; 95% CI: 0.5-0.8) glioblastomas, gross total resection (aOR: 0.8; 95% CI: 0.5-0.8) and temozolomide chemoradiotherapy (aOR 0.4; 95% CI: 0.3-0.6). Despite the significant increased administration of temozolomide chemoradiotherapy from 39% (127/326) of patients in 2006-2010 to 63% (227/356) in 2015-2019 (<i>P</i>-value < .001), median OS did not improve (2006-2010: 10.3 months vs 2015-2019: 11.8 months) (OR: 1.1; 95% CI: 0.9-1.3).</p><p><strong>Conclusions: </strong>The incidence of glioblastoma in the Chinese general population is low. We charted the development of neuro-oncological care of glioblastoma patients in Hong Kong during the temozolomide era. Although there was an increased adoption of temozolomide chemoradiotherapy, a corresponding improvement in survival was not observed.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"50-61"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837775/pdf/npac069.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10544128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey among EANO members.","authors":"","doi":"10.1093/nop/npac082","DOIUrl":"https://doi.org/10.1093/nop/npac082","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/nop/npab059.].</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"106"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/f5/npac082.PMC9837774.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10545259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions and experiences of the subjective well-being of people with glioblastoma: a longitudinal phenomenological study.","authors":"Katie Sutton,&nbsp;Jaqualyn Moore,&nbsp;Jo Armes,&nbsp;Emma Briggs","doi":"10.1093/nop/npac064","DOIUrl":"https://doi.org/10.1093/nop/npac064","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma (GBM) is a devastating form of brain cancer, with a short life expectancy. In addition to this poor prognosis, people with GBM often experience symptoms that may have a profound impact on their subjective well-being (SWB). The aim of this study was to investigate the lived experiences and perceptions of people with GBM regarding their SWB.</p><p><strong>Methods: </strong>The study adopted a longitudinal, hermeneutical phenomenological approach. Twenty-seven interviews were conducted with 15 patients over a period of two years. Most participants were interviewed twice on a face-to-face basis (during combined chemotherapy and radiotherapy, and again during adjuvant chemotherapy). The hermeneutic circle was used to guide data analysis.</p><p><strong>Results: </strong>Data analysis identified four key themes that depicted the lived experiences and perceptions of SWB of people with GBM. \"Experience of the disease\" focuses on the impact of diagnosis, symptoms and side effects. \"Daily life\" relates to daily activities, family roles, work and social lives. \"Coping\" includes the importance of normality and goal-setting. \"Experiences of care\" focuses on the impact of the treatment schedule, experiences of care and impressions of the monitoring of QoL.</p><p><strong>Conclusion: </strong>SWB is affected by a variety of factors throughout the GBM disease and treatment journey. The findings of this study suggest that healthcare professionals can enhance the SWB of people with GBM by providing personalized care that supports people to set themselves goals for the future and retain a degree of normality wherever possible.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"79-88"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9114834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in the incidence of malignant central nervous system tumors in Brazil, 2000-2015.","authors":"Letícia Lima de Oliveira,&nbsp;Anke Bergmann,&nbsp;Luiz Claudio Santos Thuler","doi":"10.1093/nop/npac063","DOIUrl":"https://doi.org/10.1093/nop/npac063","url":null,"abstract":"<p><strong>Background: </strong>In Brazil, 5870 new cases of malignant central nervous system tumors (MCNST) were estimated for men and 5220 for women for each year of the 2020-2022 triennium. The objective of this study was to analyze incidence rate trends and compare demographic characteristics of new MCNST cases according to tumor topographies in Brazil from 2000 to 2015.</p><p><strong>Methods: </strong>This study comprises an analytical cross-sectional assessment of secondary databases extracted from the Brazilian National Cancer Institute (INCA) website. Data comprised new neoplasm cases of meninges (C70), brain (C71), spinal cord, cranial nerves, and other central nervous system parts (C72) retrieved from 23 population-based cancer registries. A descriptive analysis was performed. Crude and age-adjusted incidence rates were calculated. Linear trends were calculated using a linear least squares regression for adjusted incidence rates versus time.</p><p><strong>Results: </strong>A total of 24 986 new MCNST cases were recorded. The main topography was the brain (91.5%). Except for meninges tumors, where 62.4% of the cases were observed in women, MCNST cases were more frequent among men concerning the other evaluated topographies. All 3 topographies occurred predominantly in adult patients aged from 40- to 64-year-old. Between 2000 and 2015, incidence rates ranged from 5.12 to 4.95 (a 1.4% increase of per year; 95% CI -4.0 to 6.8; <i>P</i> = .584) in men and from 4.35 to 3.61 (a 3.1% increase per year; 95% CI -1.7 to 8.0; <i>P</i> = .189).</p><p><strong>Conclusions: </strong>The most frequent topography was the brain. Incidence rates of MCNST remained relatively stable over time in both sexes.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"34-40"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837770/pdf/npac063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10021447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in patients with newly diagnosed glioblastoma.","authors":"Angela Sekely,&nbsp;Lori J Bernstein,&nbsp;Kristin L Campbell,&nbsp;Warren P Mason,&nbsp;Normand Laperriere,&nbsp;Navya Kalidindi,&nbsp;Rosemarylin Or,&nbsp;Ronald Ramos,&nbsp;Seth A Climans,&nbsp;Gregory R Pond,&nbsp;Barbara Ann Millar,&nbsp;David Shultz,&nbsp;Derek S Tsang,&nbsp;Gelareh Zadeh,&nbsp;Kim Edelstein","doi":"10.1093/nop/npac068","DOIUrl":"https://doi.org/10.1093/nop/npac068","url":null,"abstract":"<p><strong>Background: </strong>In addition to poor survival rates, individuals with glioblastoma (GBM) are at risk of neurocognitive impairment due to multiple factors. This study aimed to characterize neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms in newly diagnosed GBM patients; and to examine whether neurobehavioral symptoms, fatigue, sleep, and depressive symptoms influence neurocognitive performance.</p><p><strong>Methods: </strong>This study was part of a prospective, inception cohort, single-arm exercise intervention in which GBM patients underwent a neuropsychological assessment shortly after diagnosis (median 4 weeks; ie, baseline) and 3, 6, 12, and 18 months later, or until tumor progression. Here, we present baseline data. Forty-five GBM patients (mean age = 55 years) completed objective neurocognitive tests, and self-report measures of neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms.</p><p><strong>Results: </strong>Compared to normative samples, GBM patients scored significantly lower on all neurocognitive tests, with 34 (76%) patients exhibiting neurocognitive impairment. Specifically, 53% exhibited impairment in memory retention, 51% in executive function, 42% in immediate recall, 41% in verbal fluency, and 24% in attention. There were high rates of clinically elevated sleep disturbance (70%), fatigue (57%), depressive symptoms (16%), and neurobehavioral symptoms (27%). A multivariate regression analysis revealed that depressive symptoms are significantly associated with neurocognitive impairment.</p><p><strong>Conclusions: </strong>GBM patients are vulnerable to adverse outcomes including neurocognitive impairment, neurobehavioral symptoms, fatigue, sleep disturbance, and depressive symptoms shortly after diagnosis, prior to completing chemoradiation. Those with increased depressive symptoms are more likely to demonstrate neurocognitive impairment, highlighting the need for early identification and treatment of depression in this population.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"89-96"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837779/pdf/npac068.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10280730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of the utilization of telemedicine for brain tumor neurosurgery follow-up.","authors":"Alexis A Morell,&nbsp;Nitesh V Patel,&nbsp;Tiffany A Eatz,&nbsp;Adam S Levy,&nbsp;Daniel G Eichberg,&nbsp;Ashish H Shah,&nbsp;Evan Luther,&nbsp;Victor M Lu,&nbsp;Michael Kader,&nbsp;Dominique M O Higgins,&nbsp;Michael E Ivan,&nbsp;Ricardo J Komotar","doi":"10.1093/nop/npac060","DOIUrl":"https://doi.org/10.1093/nop/npac060","url":null,"abstract":"<p><strong>Background: </strong>There is a need to evaluate the outcomes of patients who underwent brain tumor surgery with subsequent telemedicine or in-person follow-up during the COVID-19 pandemic.</p><p><strong>Methods: </strong>We retrospectively included all patients who underwent surgery for brain tumor resection by a single neurosurgeon at our Institution from the beginning of the COVID-19 pandemic restrictions (March 2020) to August 2021. Outcomes were assessed by stratifying the patients using their preference for follow-up method (telemedicine or in-person).</p><p><strong>Results: </strong>Three-hundred and eighteen (318) brain tumor patients who were included. The follow-up method of choice was telemedicine (TM) in 185 patients (58.17%), and in-person (IP) consults in 133 patients. We found that patients followed by TM lived significantly farther, with a median of 36.34 miles, compared to a median of 22.23 miles in the IP cohort (<i>P</i> = .0025). We found no statistical difference between the TM and the IP group, when comparing visits to the emergency department (ED) within 30 days after surgery (7.3% vs 6.01%, <i>P</i> = .72). Readmission rates, wound infections, and 30-day mortality were similar in both cohorts. These findings were also consistent after matching cohorts using a propensity score. The percentage of telemedicine follow-up consults was higher in the first semester (73.17%) of the COVID-19 pandemic, compared to the second (46.21%), and third semesters (47.86%).</p><p><strong>Conclusions: </strong>Telehealth follow-up alternatives may be safely offered to patients after brain tumor surgery, thereby reducing patient burden in those with longer distances to the hospital or special situations as the COVID-19 pandemic.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"10 1","pages":"97-103"},"PeriodicalIF":2.7,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10555120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}